Harald Holte
Universitetet i Oslo
H-index: 62
Europe-Norway
Top articles of Harald Holte
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab
British journal of haematology
2024/1
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
Blood
2023/11/28
Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas
Blood
2023/11/28
Harald Holte
H-Index: 36
Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL
Blood
2023/11/28
Ankush Sharma
H-Index: 7
Sigve Nakken
H-Index: 16
Harald Holte
H-Index: 36
June Helen Myklebust
H-Index: 21
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
Haematologica
2023/11/11
Harald Holte
H-Index: 36
Klaus Beiske
H-Index: 22
MetaGate: Interactive Analysis of High-Dimensional Cytometry Data with Meta Data Integration
bioRxiv
2023/11/1
Arne Kolstad
H-Index: 28
Harald Holte
H-Index: 36
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma
Blood cancer journal
2023/10/26
Klaus Beiske
H-Index: 22
Harald Holte
H-Index: 36
Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy
Leukemia & lymphoma
2023/10/15
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms
Leukemia
2023/10
The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
Haematologica
2023/9/9
Knut Liestøl
H-Index: 32
Harald Holte
H-Index: 36
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study
International Journal of Cancer
2023/8/15
Caroline E Weibull
H-Index: 13
Harald Holte
H-Index: 36
Alexander Fosså
H-Index: 20
Sandra Eloranta
H-Index: 24
S222: Epcoritamab with rituximab+ lenalidomide (R2) provides durable responses in patients with high-risk follicular lymphoma, regardless of POD24 status
HemaSphere
2023/8/1
Reproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study
British Journal of Haematology
2023/8
Caroline E Weibull
H-Index: 13
Harald Holte
H-Index: 36
Alexander Fosså
H-Index: 20
Sandra Eloranta
H-Index: 24
Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score
Leukemia & lymphoma
2023/7/3
Harald Holte
H-Index: 36
Arne Kolstad
H-Index: 28
Mats Jerkeman
H-Index: 32
Lasse Sommer Kristensen
H-Index: 20
LONG‐TERM FOLLOW‐UP AND GENE EXPRESSION PROFILES ASSOCIATED WITH OUTCOME IN PATIENTS WITH RELAPSED AGGRESSIVE B‐OR T‐CELL LYMPHOMAS TREATED IN THE NORDIC P [R] EBEN TRIAL
Hematological Oncology
2023/6
Epcoritamab WITH Rituximab+ Lenalidomide (R2) Provides Durable Responses In High-Risk Follicular Lymphoma, Regardless Of POD24 Status
International Conference on Malignant Lymphoma
2023/6
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CELL LYMPHOMA (NLG‐LBC‐06 PHASE II TRIAL): IMPACT OF CTDNA AND TP53 ABERRATIONS ON CLINICAL OUTCOME
Hematological Oncology
2023/6
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.
2023/6/1
Epcoritamab+ RSUP2/SUP regimen and responses in patients with high-risk follicular lymphoma, regardless of POD24 status
2023
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Advances
2023/12/12
